These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3014743)

  • 1. Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurization.
    Hilfenhaus J; Herrmann A; Mauler R; Prince AM
    Vox Sang; 1986; 50(4):208-11. PubMed ID: 3014743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of human blood products: inactivation of retroviruses by heat treatment at 60 degrees C.
    Hilfenhaus J; Mauler R; Friis R; Bauer H
    Proc Soc Exp Biol Med; 1985 Apr; 178(4):580-4. PubMed ID: 2984690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
    Hilfenhaus J; Nowak T
    Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
    Mauler R; Merkle W; Hilfenhaus J
    Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
    Hilfenhaus J; Weidmann E
    Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.
    McDougal JS; Martin LS; Cort SP; Mozen M; Heldebrant CM; Evatt BL
    J Clin Invest; 1985 Aug; 76(2):875-7. PubMed ID: 2993366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
    Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
    Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of AIDS-causing retroviruses by the manufacturing procedures for human plasma proteins.
    Hilfenhaus J; Gregersen JP
    Behring Inst Mitt; 1988 Apr; (82):82-93. PubMed ID: 3044347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
    Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
    Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses.
    Sullivan JL; Brewster FE; Brettler DB; Forsberg AD; Cheeseman SH; Byron KS; Baker SM; Willitts DL; Lew RA; Levine PH
    J Pediatr; 1986 Apr; 108(4):504-10. PubMed ID: 3007715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of hepatitis A virus by heat treatment in aqueous solution.
    Murphy P; Nowak T; Lemon SM; Hilfenhaus J
    J Med Virol; 1993 Sep; 41(1):61-4. PubMed ID: 8228940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
    Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus validation experiments on the production process of OCTAVI SDPlus.
    Biesert L; Lemon S; Suhartono H; Wang L; Rübsamen H
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S48-54. PubMed ID: 7495968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of a heat treated antihaemophilic cryoprecipitate.
    Skjønsberg OH; Gravem K; Kierulf P; Godal HC
    Thromb Res; 1987 Mar; 45(5):625-34. PubMed ID: 3109063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
    Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
    Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
    Prince AM; Horowitz B; Brotman B
    Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible viral interactions in the acquired immunodeficiency syndrome (AIDS).
    Hirsch MS; Schooley RT; Ho DD; Kaplan JC
    Rev Infect Dis; 1984; 6(5):726-31. PubMed ID: 6095405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U; Drewke E
    Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.